Can Hydroquinone Cause White or Dark Patches on Skin? What Australians Need to Know

Hydroquinone (HQ) is the gold standard in treating melasma and hyperpigmentation. But misinformation online has created confusion – especially around whether HQ can cause white patches or destroy pigment (aka hypopigmentation).

Let’s unpack what the science really says, especially for Australians using HQ under proper medical supervision.

Understanding the Confusion Around Hydroquinone

Hydroquinone’s reputation often suffers due to Exogenous Ochronosis (EO) – a blue-grey skin discolouration that is extremely rare and mostly associated with unsupervised, long-term use or black market bleaching creams.

But what about hypopigmentation – the loss of pigment or white patches on skin?

To provide some perspective around how frequently hypopigmentation occurs with hydroquinone, let’s first understand just how rarely the more common side effect, EO, is actually reported, and under what circumstances:

How Rare is EO? Let’s Look at the Data

A 2007 systematic review identified 789 total EO cases reported worldwide since 1966.

Most cases were people who had used HQ continuously for years (not months of use as we prescribe).

95% (756/789) of these reported cases were from Africa where the nature of the HQ was unknown. This is because there’s a huge black market in skin ‘bleaching’ creams that can contain just about anything. This can include very high doses of HQ combined with other EO-causing ingredients like phenol and resorcinol. EO can also result from the use of antimalarial drugs, widely used in Africa.

Of the 137 cases that reported the concentration of HQ used, the majority (116) used a very low dose of 1-2%, but usage was unsupervised and excessive, with multiple daily applications

22 of these 789 cases were from the USA and involved the use of 1–2% hydroquinone used without supervision for years. These cases were reported from 1983–2006, which equates to 1 case per year, during which time an estimated 10–15 million HQ–containing creams/year were sold, making EO incidence 0.00022% to 0.0000067% during this period.

In a second study analysing 20,814 patients who were prescribed 2-5% topical HQ for 8 weeks to 2 years, and closely medically supervised throughout this time, there were ZERO reports of EO.

Now you know just how rare EO actually is, what about hypopigmentation?

An analysis of the scientific literature about hypopigmentation as a side effect of HQ use shows a similar pattern of unsupervised, non-medical use of potentially black market formulas (that could contain anything), and including use of hydroquinone in a work environment.

It is also reported when HQ has been used in conjunction with lasers/peels, which have a very high risk of hypopigmentation as they create intentional damage to the skin.

There have been 5 reported cases of hypopigmentation in total in the scientific literature, making it an extraordinarily rare side effect – way more so than the extremely rare side effect of EO.

But… If you Google HQ and hypopigmentation, some scientific references say they are related!

These are often referring to use of a derivative of HQ called Monobenzone. The other name for this is  ‘Monobenzylether of Hydroquinone’ – and it can be easily confused for HQ itself.

Monobenzone is a drug intentionally used by doctors to permanently hypopigment (or depigment) skin when treating the skin disease vitiligo.

So, in these instances hypopigmentation is an intended side effect to even out the skin tone. We do not use this drug at Qr8. 

Have you ever seen a case of EO or hypopigmentation at Qr8?

Since 2019, when our service launched, our doctors have treated thousands of patients of all skin tones with up to 12% hydroquinone daily and we have never had an incidence of EO or hypopigmentation.

How Qr8’s Approach Minimises Even Rare Risks

Regardless, we are cautious of even rare side effects like EO and hypopigmentation, which is why our service is designed specifically to minimise irritation (trauma can result in death of melanocytes and hypopigmentation, which is why hypopigmentation is a common side effect of laser/peels).

We do this by carefully and slowly phasing your treatment in, providing information about skincare to support your treatment and reduce irritation, and closely supervise all patients using HQ, mandating 3 monthly checks with their doctor.

We also package our creams in medical-grade packaging to minimise oxygen exposure so they last for the 3 months of your treatment cycle, as a chemical formed by degraded hydroquinone (called ‘hydroxybenzoquinone’) can damage cells, leading to hypopigmentation.

We also send reminders so you can rebook with your doctor as your 3 month treatment period ends, to avoid you using expired and degraded creams, thereby potentially damaging your skin.

As an active patient, you also have access to our Clinical Support Team of nurses and dermal therapists by email, phone or video, so can contact them if you are concerned about anything (and we respond within 24 business hours – usually much sooner!).